{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T19:17:16Z","timestamp":1769973436086,"version":"3.49.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T00:00:00Z","timestamp":1562112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"MRC NIHR Efficacy and Mechanism Evaluation","award":["10\/60\/37"],"award-info":[{"award-number":["10\/60\/37"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Combination antiretroviral therapy results in metabolic abnormalities which increase cardiovascular disease risk. We evaluated whether telmisartan reduces insulin resistance in human immunodeficiency virus (HIV)\u2013positive individuals on antiretrovirals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a multicenter, randomized, open-label, dose-ranging controlled trial of telmisartan. Participants with HIV infection receiving combination antiretroviral therapy were randomized equally to either no intervention (control) or 20, 40, or 80 mg telmisartan once daily. The adaptive design allowed testing of all dose(s) of telmisartan in stage I, with the promising dose(s) being taken into stage II. The primary outcome measure was reduction in homeostasis model assessment of insulin resistance (HOMA-IR) at 24 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 377 patients were recruited. In stage I, 48, 49, 47, and 45 patients were randomized to control and 20, 40, and 80 mg telmisartan, respectively (total n = 189). At the interim analysis, 80 mg telmisartan was taken forward into stage II. At the end of stage II (n = 105, control; 106, 80-mg arm), there were no differences in HOMA-IR (estimated effect, 0.007; SE, 0.106) at 24 weeks between the telmisartan (80 mg) and nonintervention arms. Longitudinal analysis over 48 weeks showed no change in HOMA-IR, lipid or adipokine levels. There were significant (P \u2264 .05), but marginal, improvements in revised Quantitative Insulin Sensitivity Check Index (QUICKI) (0.004) and plasma hs-CRP (\u22120.222 mg\/L) and reduction in liver fat content (1.714 mean reduction; P = .005).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>No significant effect of telmisartan was demonstrated on the primary outcome (HOMA-IR), but there were marginal improvements with some secondary outcome measures. Further studies in this population are warranted to identify novel strategies for preventing cardiovascular morbidity and mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trial Registration<\/jats:title><jats:p>ISRCTN registry (51069819).<\/jats:p><\/jats:sec>","DOI":"10.1093\/cid\/ciz589","type":"journal-article","created":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T11:13:10Z","timestamp":1562065990000},"page":"2062-2072","source":"Crossref","is-referenced-by-count":15,"title":["TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy"],"prefix":"10.1093","volume":"70","author":[{"given":"Sudeep","family":"Pushpakom","sequence":"first","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology, University of Liverpool, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruwanthi","family":"Kolamunnage-Dona","sequence":"first","affiliation":[{"name":"Department of Biostatistics, University of Liverpool, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Taylor","sequence":"first","affiliation":[{"name":"Clinical Trials Research Centre, University of Liverpool, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry","family":"Foster","sequence":"first","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology, University of Liverpool, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cath","family":"Spowart","sequence":"first","affiliation":[{"name":"Clinical Trials Research Centre, University of Liverpool, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Garc\u00eda-Fi\u00f1ana","sequence":"first","affiliation":[{"name":"Department of Biostatistics, University of Liverpool, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham J","family":"Kemp","sequence":"first","affiliation":[{"name":"Liverpool Magnetic Resonance Imaging Centre, University of Liverpool, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Jaki","sequence":"first","affiliation":[{"name":"Department of Mathematics and Statistics, Lancaster University, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saye","family":"Khoo","sequence":"first","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology, University of Liverpool, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Williamson","sequence":"first","affiliation":[{"name":"Department of Biostatistics, University of Liverpool, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munir","family":"Pirmohamed","sequence":"first","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology, University of Liverpool, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the TAILoR Study Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Ainsworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Chadwick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mas","family":"Chaponda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayur","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duncan","family":"Churchill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satyajit","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Gompels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elbushra","family":"Hereika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clifford","family":"Leen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Loay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiola","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Minton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Post","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Schembri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiten","family":"Vora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Whitehead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,7,3]]},"reference":[{"key":"2020050606280052100_CIT0001","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1089\/aid.2015.0147","article-title":"Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada","volume":"32","author":"Koethe","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2020050606280052100_CIT0002","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/S1473-3099(13)70271-8","article-title":"Metabolic disease in HIV infection","volume":"13","author":"Lake","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"2020050606280052100_CIT0003","doi-asserted-by":"crossref","first-page":"e0150970","DOI":"10.1371\/journal.pone.0150970","article-title":"A meta-analysis of the metabolic syndrome prevalence in the global HIV-infected population","volume":"11","author":"Nguyen","year":"2016","journal-title":"PLoS One"},{"key":"2020050606280052100_CIT0004","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa030218","article-title":"Combination antiretroviral therapy and the risk of myocardial infarction","volume":"349","author":"Friis-M\u00f8ller","year":"2003","journal-title":"N Engl J Med"},{"key":"2020050606280052100_CIT0005","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/QAD.0b013e328334344e","article-title":"High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome","volume":"24","author":"Worm","year":"2010","journal-title":"AIDS"},{"key":"2020050606280052100_CIT0006","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa062744","article-title":"Class of antiretroviral drugs and the risk of myocardial infarction","volume":"356","author":"Friis-Moller","year":"2007","journal-title":"N Engl J Med"},{"key":"2020050606280052100_CIT0007","doi-asserted-by":"crossref","first-page":"F17","DOI":"10.1097\/QAD.0b013e32830fe35e","article-title":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients","volume":"22","author":"The SMART\/INSIGHT and the D:A:D study groups","year":"2008","journal-title":"AIDS"},{"key":"2020050606280052100_CIT0008","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/cid\/civ316","article-title":"Risk of cardiovascular events associated with current exposure to HIV antiretroviral therapies in a US veteran population","volume":"61","author":"Desai","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020050606280052100_CIT0009","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1463-1326.2005.00521.x","article-title":"Insulin resistance\u2014a common link between type 2 diabetes and cardiovascular disease","volume":"8","author":"Lebovitz","year":"2006","journal-title":"Diabetes Obes Metab"},{"key":"2020050606280052100_CIT0010","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bbrc.2009.05.148","article-title":"Lopinavir co-induces insulin resistance and ER stress in human adipocytes","volume":"386","author":"Djedaini","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"2020050606280052100_CIT0011","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1097\/QAD.0b013e32826fbc54","article-title":"Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers","volume":"21","author":"Lee","year":"2007","journal-title":"AIDS"},{"key":"2020050606280052100_CIT0012","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1157\/13108348","article-title":"[Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz, lopinavir\/ritonavir and atazanavir.]","volume":"129","author":"Bernal","year":"2007","journal-title":"Med Clin"},{"key":"2020050606280052100_CIT0013","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1177\/135965350601100413","article-title":"Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy","volume":"11","author":"Palacios","year":"2006","journal-title":"Antivir Ther"},{"key":"2020050606280052100_CIT0014","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1530\/EJE-14-0337","article-title":"Prevalence of insulin resistance and risk of diabetes mellitus in HIV-infected patients receiving current antiretroviral drugs","volume":"171","author":"Araujo","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"2020050606280052100_CIT0015","doi-asserted-by":"crossref","first-page":"ofw174","DOI":"10.1093\/ofid\/ofw174","article-title":"Changes in insulin resistance after initiation of raltegravir or protease inhibitors with tenofovir-emtricitabine: AIDS Clinical Trials Group A5260s","volume":"3","author":"Dirajlal-Fargo","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"2020050606280052100_CIT0016","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1345\/aph.1D081","article-title":"Pharmacologic therapy for HIV-associated lipodystrophy","volume":"38","author":"Benavides","year":"2004","journal-title":"Ann Pharmacother"},{"key":"2020050606280052100_CIT0017","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1468-1293.2007.00480.x","article-title":"The management of dyslipidaemias in antiretroviral-treated HIV infection: a systematic review","volume":"8","author":"McGoldrick","year":"2007","journal-title":"HIV Med"},{"key":"2020050606280052100_CIT0018","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"2020050606280052100_CIT0019","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/1471-2334-10-183","article-title":"The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials","volume":"10","author":"Sheth","year":"2010","journal-title":"BMC Infect Dis"},{"key":"2020050606280052100_CIT0020","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2710.2007.00820.x","article-title":"Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone","volume":"32","author":"Derosa","year":"2007","journal-title":"J Clin Pharm Ther"},{"key":"2020050606280052100_CIT0021","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.clinthera.2010.03.018","article-title":"Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study","volume":"32","author":"Rizos","year":"2010","journal-title":"Clin Ther"},{"key":"2020050606280052100_CIT0022","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"2020050606280052100_CIT0023","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jash.2014.05.006","article-title":"A meta-analysis of randomized trials of telmisartan versus active controls for insulin resistance in hypertensive patients","volume":"8","author":"Takagi","year":"2014","journal-title":"J Am Soc Hypertens"},{"key":"2020050606280052100_CIT0024","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0149-2918(04)80049-3","article-title":"Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study","volume":"26","author":"Derosa","year":"2004","journal-title":"Clin Ther"},{"key":"2020050606280052100_CIT0025","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1291\/hypres.27.457","article-title":"Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study","volume":"27","author":"Derosa","year":"2004","journal-title":"Hypertens Res"},{"key":"2020050606280052100_CIT0026","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1074\/jbc.M408687200","article-title":"Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines","volume":"280","author":"Vernochet","year":"2005","journal-title":"J Biol Chem"},{"key":"2020050606280052100_CIT0027","first-page":"1479164118757924","article-title":"Telmisartan reverses antiretroviral-induced adipocyte toxicity and insulin resistance in vitro","author":"Pushpakom","year":"2018","journal-title":"Diab Vasc Dis Res"},{"key":"2020050606280052100_CIT0028","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3851\/IMP1533","article-title":"HIV protease inhibitors activate the adipocyte renin angiotensin system","volume":"15","author":"Boccara","year":"2010","journal-title":"Antivir Ther"},{"key":"2020050606280052100_CIT0029","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.2337\/diabetes.54.12.3442","article-title":"Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity","volume":"54","author":"Schupp","year":"2005","journal-title":"Diabetes"},{"key":"2020050606280052100_CIT0030","doi-asserted-by":"crossref","first-page":"e58135","DOI":"10.1371\/journal.pone.0058135","article-title":"A pilot study of telmisartan for visceral adiposity in HIV infection: the Metabolic Abnormalities, Telmisartan, and HIV Infection (MATH) trial","volume":"8","author":"Lake","year":"2013","journal-title":"PLoS One"},{"key":"2020050606280052100_CIT0031","doi-asserted-by":"crossref","first-page":"e009566","DOI":"10.1136\/bmjopen-2015-009566","article-title":"Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy","volume":"5","author":"Pushpakom","year":"2015","journal-title":"BMJ Open"},{"key":"2020050606280052100_CIT0032","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/biomet\/ass002","article-title":"A generalized Dunnett test for multi-arm multistage clinical studies with treatment selection","volume":"99","author":"Magirr","year":"2012","journal-title":"Biometrika"},{"key":"2020050606280052100_CIT0033","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/sim.3508","article-title":"One- and two-stage design proposals for a phase II trial comparing three active treatments with control using an ordered categorical endpoint","volume":"28","author":"Whitehead","year":"2009","journal-title":"Stat Med"},{"key":"2020050606280052100_CIT0034","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/biostatistics\/1.4.465","article-title":"Joint modelling of longitudinal measurements and event time data","volume":"1","author":"Henderson","year":"2000","journal-title":"Biostatistics"},{"key":"2020050606280052100_CIT0035","doi-asserted-by":"crossref","first-page":"6426","DOI":"10.1002\/sim.3451","article-title":"Joint modelling of longitudinal and competing risks data","volume":"27","author":"Williamson","year":"2008","journal-title":"Stat Med"},{"key":"2020050606280052100_CIT0036","first-page":"491","article-title":"Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan","volume":"16","author":"Ucciferri","year":"2012","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2020050606280052100_CIT0037","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3851\/IMP1809","article-title":"Antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive patients","volume":"16","author":"Vecchiet","year":"2011","journal-title":"Antivir Ther"},{"key":"2020050606280052100_CIT0038","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1038\/nutd.2015.24","article-title":"Ethnic differences in insulin sensitivity and beta-cell function among Asian men","volume":"5","author":"Tan","year":"2015","journal-title":"Nutr Diabetes"},{"key":"2020050606280052100_CIT0039","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s00125-014-3285-x","article-title":"Surrogate measures of insulin sensitivity vs the hyperinsulinaemic-euglycaemic clamp: a meta-analysis","volume":"57","author":"Otten","year":"2014","journal-title":"Diabetologia"},{"key":"2020050606280052100_CIT0040","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1210\/jcem.86.10.7902","article-title":"Incorporation of the fasting plasma FFA concentration into QUICKI improves its association with insulin sensitivity in nonobese individuals","volume":"86","author":"Perseghin","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020050606280052100_CIT0041","doi-asserted-by":"crossref","first-page":"15430","DOI":"10.1073\/pnas.0904944106","article-title":"Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity","volume":"106","author":"Fabbrini","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020050606280052100_CIT0042","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/j.clinthera.2009.10.010","article-title":"Prospective, randomized, single-blind comparison of effects of 6 months of treatment with telmisartan versus enalapril on high-molecular-weight adiponectin concentrations in patients with coronary artery disease","volume":"31","author":"Satoh","year":"2009","journal-title":"Clin Ther"},{"key":"2020050606280052100_CIT0043","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ijcard.2012.01.104","article-title":"Effects of telmisartan on C-reactive protein levels: a meta-analysis of randomized controlled trials","volume":"156","author":"Takagi","year":"2012","journal-title":"Int J Cardiol"},{"key":"2020050606280052100_CIT0044","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1186\/1471-2334-13-414","article-title":"The association of high-sensitivity C-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study","volume":"13","author":"De Luca","year":"2013","journal-title":"BMC Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz589\/29187796\/ciz589.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/70\/10\/2062\/33174568\/ciz589.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/70\/10\/2062\/33174568\/ciz589.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T18:43:50Z","timestamp":1663872230000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/70\/10\/2062\/5527878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,3]]},"references-count":44,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,7,3]]},"published-print":{"date-parts":[[2020,5,6]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz589","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5,15]]},"published":{"date-parts":[[2019,7,3]]}}}